NPS Pharmaceuticals Enterprise Value:
1.316B for May 17, 2013NPS Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 1.316B |
| May 16, 2013 | 1.270B |
| May 15, 2013 | 1.315B |
| May 14, 2013 | 1.331B |
| May 13, 2013 | 1.335B |
| May 10, 2013 | 1.324B |
| May 9, 2013 | 1.285B |
| May 8, 2013 | 1.251B |
| May 7, 2013 | 1.237B |
| May 6, 2013 | 1.234B |
| May 3, 2013 | 1.227B |
| May 2, 2013 | 1.225B |
| May 1, 2013 | 1.205B |
| April 30, 2013 | 1.242B |
| April 29, 2013 | 1.265B |
| April 26, 2013 | 1.248B |
| April 25, 2013 | 1.258B |
| April 24, 2013 | 1.224B |
| April 23, 2013 | 1.226B |
| April 22, 2013 | 1.197B |
| April 19, 2013 | 1.175B |
| April 18, 2013 | 1.115B |
| April 17, 2013 | 1.141B |
| April 16, 2013 | 1.135B |
| April 15, 2013 | 1.107B |
| April 12, 2013 | 1.131B |
| April 11, 2013 | 1.123B |
| April 10, 2013 | 1.162B |
| April 9, 2013 | 1.091B |
| April 8, 2013 | 1.058B |
| April 5, 2013 | 1.024B |
| April 4, 2013 | 1.015B |
| April 3, 2013 | 993.75M |
| April 2, 2013 | 949.43M |
| April 1, 2013 | 939.00M |
| March 28, 2013 | 962.03M |
| March 27, 2013 | 931.18M |
| March 26, 2013 | 935.53M |
| March 25, 2013 | 933.79M |
| March 22, 2013 | 934.66M |
| March 21, 2013 | 930.31M |
| March 20, 2013 | 916.41M |
| March 19, 2013 | 933.79M |
| March 18, 2013 | 860.78M |
| March 15, 2013 | 872.95M |
| March 14, 2013 | 846.01M |
| March 13, 2013 | 798.21M |
| March 12, 2013 | 785.17M |
| March 11, 2013 | 789.52M |
| March 8, 2013 | 788.65M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
NPSP Enterprise Value Benchmarks
| Companies | |
|---|---|
| Vertex Pharmaceuticals | 16.99B |
| Celgene Corporation | 51.71B |
| ACADIA Pharmaceuticals | 942.55M |
NPSP Enterprise Value Rankings
| Overall |
75th percentile 1885 of 7593 |
| Sector |
77th percentile 149 of 650 in Healthcare |
| Industry |
87th percentile 30 of 237 in Biotechnology |
NPSP Enterprise Value Range, Past 5 Years
| Minimum | 48.01M | Jun 2 2009 |
| Maximum | 1.335B | May 13 2013 |
| Average | 609.17M |
